Dr. Finn on Role of Lenvatinib in HCC Treatment Paradigm

Richard Finn, MD
Published: Sunday, Sep 16, 2018



Richard Finn, MD, professor of clinical medicine in the Division of Hematology and Oncology, director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles, discusses the role lenvatinib (Lenvima) in the treatment paradigm for advanced hepatocellular carcinoma (HCC).

Lenvatinib was approved worldwide on the basis of its demonstrated noninferiority to sorafenib (Nexavar) in the frontline setting of advanced HCC. Researchers have reported that treatment with lenvatinib increases response rates, and overall survival between patients treated with lenvatinib and sorafenib is equivalent.

Because lenvatinib has a different toxicity profile than sorafenib, looking at patient factors such as comorbidities and underlying liver disease will be important. Evaluating tumor characteristics will also be key. While response does not necessarily correlate with survival, response in patients whose livers have a high tumor burden versus stable disease may be important.

View more from the 2018 International Liver Cancer Association Annual Conference

Brought to you in part by Eisai


Richard Finn, MD, professor of clinical medicine in the Division of Hematology and Oncology, director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles, discusses the role lenvatinib (Lenvima) in the treatment paradigm for advanced hepatocellular carcinoma (HCC).

Lenvatinib was approved worldwide on the basis of its demonstrated noninferiority to sorafenib (Nexavar) in the frontline setting of advanced HCC. Researchers have reported that treatment with lenvatinib increases response rates, and overall survival between patients treated with lenvatinib and sorafenib is equivalent.

Because lenvatinib has a different toxicity profile than sorafenib, looking at patient factors such as comorbidities and underlying liver disease will be important. Evaluating tumor characteristics will also be key. While response does not necessarily correlate with survival, response in patients whose livers have a high tumor burden versus stable disease may be important.

View more from the 2018 International Liver Cancer Association Annual Conference

Brought to you in part by Eisai

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x